First IPF Patient Enrolled in Phase 3 Study of Tyvaso

First IPF Patient Enrolled in Phase 3 Study of Tyvaso

295837

First IPF Patient Enrolled in Phase 3 Study of Tyvaso

The first participant has been enrolled in a Phase 3 trial to evaluate the impact of United Therapeutics’ Tyvaso (inhaled treprostinil) on lung function in adults with idiopathic pulmonary fibrosis (IPF). The trial, TETON (NCT04708782), aims to recruit approximately 396 people ages 40 and older, who will undergo treatment for one year, followed by an approximately two-year open-label extension study (NCT04905693). “Despite the availability of two approved products in the therapeutic category, there remains a…

You must be logged in to read/download the full post.